Biocure Technology Balance Sheet Health
Financial Health criteria checks 4/6
Biocure Technology has a total shareholder equity of CA$1.6M and total debt of CA$43.7K, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are CA$2.0M and CA$399.2K respectively.
Key information
2.8%
Debt to equity ratio
CA$43.68k
Debt
Interest coverage ratio | n/a |
Cash | CA$3.53k |
Equity | CA$1.58m |
Total liabilities | CA$399.22k |
Total assets | CA$1.98m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CURE.X's short term assets (CA$13.1K) do not cover its short term liabilities (CA$355.5K).
Long Term Liabilities: CURE.X's short term assets (CA$13.1K) do not cover its long term liabilities (CA$43.7K).
Debt to Equity History and Analysis
Debt Level: CURE.X's net debt to equity ratio (2.5%) is considered satisfactory.
Reducing Debt: CURE.X's debt to equity ratio has reduced from 114.1% to 2.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CURE.X has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CURE.X is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.6% per year.